Can-Fite BioPharma Publishes Study on Namodenoson
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy CANF?
Can-Fite BioPharma announced the publication of a peer-reviewed study in the International Journal of Obesity demonstrating the anti-obesity effect of namodenoson, the Company's lead drug candidate. The article, titled "The anti-obesity effect of namodenoson, an A3 adenosine receptor agonist," is now available online as an Open Access publication. The study evaluated the effects of namodenoson in adipocytes in vitro and in a murine high-fat diet model of obesity. The findings are consistent with previously reported data from a Phase IIa clinical study in patients with metabolic dysfunction-associated steatohepatitis, in which treatment with namodenoson for three months was associated with reductions in liver fat and body weight. A Phase IIb MASH study is currently enrolling patients and is designed to evaluate effects on inflammation, fibrosis, steatosis, and body weight.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CANF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CANF
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Can-Fite BioPharma's Drug Trial Achieves Success
- Clinical Trial Success: Can-Fite BioPharma's investigational drug Namodenoson successfully met the primary endpoint in a Phase 2a study for advanced pancreatic ductal adenocarcinoma, demonstrating excellent tolerability with no new safety signals, indicating its potential in a difficult-to-treat patient population.
- Survival Rate Tracking: While the primary endpoint has been achieved, secondary endpoints such as overall survival and progression-free survival are still being monitored, with one-third of patients alive at the data cut-off, suggesting the potential for sustained therapeutic effects of Namodenoson.
- Financing Activity: On the same day, Can-Fite announced the immediate exercise of certain outstanding warrants to purchase up to 795,869 ADSs at $9.34 per ADS, generating approximately $4 million in gross proceeds, reflecting the company's proactive financial strategy.
- R&D Investment Plans: The company intends to use the net proceeds to fund ongoing research, clinical trials, and general corporate purposes, further advancing its pipeline of small-molecule drugs targeting cancer, liver, and inflammatory diseases, with Namodenoson positioned as a key candidate in multiple late-stage trials.
See More
Can-Fite BioPharma's Drug Trial Success Boosts Shares
- Clinical Trial Success: Can-Fite BioPharma announced that its drug Namodenoson successfully met the primary endpoint in a Phase 2a study for pretreated pancreatic cancer patients, demonstrating significant survival rate improvements, which analysts view as a promising development for the company's future prospects.
- Good Safety Profile: The drug exhibited good tolerability and safety during trials, with secondary endpoints including overall survival and progression-free survival; at the data cut-off, one-third of patients remained alive, and further survival outcomes are expected to mature and be announced at upcoming scientific meetings.
- Expanded Clinical Trials: Can-Fite is focusing on expanding its clinical trials to further explore Namodenoson's efficacy in advanced liver cancer, indicating the company's ongoing commitment and research potential in cancer treatment, with topline efficacy data expected in Q3 2026.
- Intellectual Property Protection: Can-Fite received a Canadian patent for Namodenoson’s use in reducing fat mass and body weight, enhancing its intellectual property protection as an anti-obesity therapy, which broadens the drug's potential indications and strengthens its market competitiveness.
See More
Can-Fite BioPharma Completes Financing Agreement
- Financing Agreement Reached: Can-Fite BioPharma has entered into an agreement with H.C. Wainwright & Co. for the immediate exercise of 795,869 warrants, reducing the exercise price from $9.34 to $5.00, with expected proceeds of approximately $4 million to enhance liquidity for R&D and clinical trials.
- New Warrants Issued: In exchange for cash exercise of the warrants, Can-Fite will issue 1,591,738 new warrants at an exercise price of $5.00, valid for 24 months, aimed at further incentivizing investors and boosting market confidence.
- Registration Statement Filing: Can-Fite has agreed to file a registration statement with the SEC covering the ADSs issuable upon exercise of the new warrants, ensuring compliance and paving the way for future financing while enhancing company transparency.
- Clinical Trial Progress: Can-Fite's lead drug candidates, Piclidenoson and Namodenoson, are undergoing pivotal Phase III clinical trials, which, if successful, could tap into multi-billion dollar markets, further solidifying the company's position in the biopharmaceutical sector.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 100 Points
- Dow Jones Performance: The Dow Jones index gained over 100 points on Wednesday, rising 0.25% to close at 48,622.74, indicating positive market sentiment and increased investor confidence.
- NASDAQ and S&P 500 Rise: The NASDAQ climbed 0.69% to 22,672.12, while the S&P 500 rose 0.37% to 6,841.53, reflecting strong performances in the technology and consumer sectors.
- Abercrombie & Fitch Earnings: The company reported Q4 earnings of $3.68 per share, beating analyst expectations of $3.57, yet its stock fell around 5%, indicating market concerns about future performance.
- Private Sector Job Data: U.S. private businesses added 63,000 jobs in February, significantly exceeding market estimates of 50,000, suggesting a robust economic recovery that could positively impact the stock market.
See More
Can-Fite BioPharma Shares Surge 40% on Positive Trial Results
- Clinical Trial Success: Can-Fite BioPharma reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma, leading to a more than 40% surge in pre-market trading.
- Safety Endpoint Met: The trial met its primary safety endpoint, demonstrating that the drug was very well tolerated with no new safety concerns, indicating its potential for use in high-risk patients.
- Patient Recruitment: The study enrolled 20 high-risk patients who had previously received one or more therapies, highlighting the drug's prospects in treating refractory cancer cases.
- FDA Orphan Drug Designation: Namodenoson has received Orphan Drug Designation from the U.S. FDA for pancreatic cancer treatment, further enhancing its market potential and research value.
See More
UiPath to Join S&P Midcap 400 Index Effective January 2, 2026
- Market Focus: UiPath Inc. announced it will join the S&P Midcap 400 Index on January 2, 2026, replacing Synovus Financial Corp., a move expected to enhance the company's visibility and investor confidence.
- Stock Price Surge: Following this announcement, UiPath shares rose 6.8% to $17.05 in after-hours trading, reflecting market optimism regarding its future performance.
- FDA Approval: Agios Pharmaceuticals' AQVESME™ (mitapivat) received FDA approval for treating anemia in adults with alpha- or beta-thalassemia, although its stock fell 1.4%, this approval could pave the way for future sales growth.
- Stock Buyback Plan: Ramaco Resources announced a $100 million stock repurchase plan, with shares jumping 7.1% in after-hours trading, indicating the company's confidence in its value and potentially attracting more investor interest.
See More
Can-Fite BioPharma's Drug Trial Achieves Success
- Clinical Trial Success: Can-Fite BioPharma's investigational drug Namodenoson successfully met the primary endpoint in a Phase 2a study for advanced pancreatic ductal adenocarcinoma, demonstrating excellent tolerability with no new safety signals, indicating its potential in a difficult-to-treat patient population.
- Survival Rate Tracking: While the primary endpoint has been achieved, secondary endpoints such as overall survival and progression-free survival are still being monitored, with one-third of patients alive at the data cut-off, suggesting the potential for sustained therapeutic effects of Namodenoson.
- Financing Activity: On the same day, Can-Fite announced the immediate exercise of certain outstanding warrants to purchase up to 795,869 ADSs at $9.34 per ADS, generating approximately $4 million in gross proceeds, reflecting the company's proactive financial strategy.
- R&D Investment Plans: The company intends to use the net proceeds to fund ongoing research, clinical trials, and general corporate purposes, further advancing its pipeline of small-molecule drugs targeting cancer, liver, and inflammatory diseases, with Namodenoson positioned as a key candidate in multiple late-stage trials.
See More
Can-Fite BioPharma's Drug Trial Success Boosts Shares
- Clinical Trial Success: Can-Fite BioPharma announced that its drug Namodenoson successfully met the primary endpoint in a Phase 2a study for pretreated pancreatic cancer patients, demonstrating significant survival rate improvements, which analysts view as a promising development for the company's future prospects.
- Good Safety Profile: The drug exhibited good tolerability and safety during trials, with secondary endpoints including overall survival and progression-free survival; at the data cut-off, one-third of patients remained alive, and further survival outcomes are expected to mature and be announced at upcoming scientific meetings.
- Expanded Clinical Trials: Can-Fite is focusing on expanding its clinical trials to further explore Namodenoson's efficacy in advanced liver cancer, indicating the company's ongoing commitment and research potential in cancer treatment, with topline efficacy data expected in Q3 2026.
- Intellectual Property Protection: Can-Fite received a Canadian patent for Namodenoson’s use in reducing fat mass and body weight, enhancing its intellectual property protection as an anti-obesity therapy, which broadens the drug's potential indications and strengthens its market competitiveness.
See More
Can-Fite BioPharma Completes Financing Agreement
- Financing Agreement Reached: Can-Fite BioPharma has entered into an agreement with H.C. Wainwright & Co. for the immediate exercise of 795,869 warrants, reducing the exercise price from $9.34 to $5.00, with expected proceeds of approximately $4 million to enhance liquidity for R&D and clinical trials.
- New Warrants Issued: In exchange for cash exercise of the warrants, Can-Fite will issue 1,591,738 new warrants at an exercise price of $5.00, valid for 24 months, aimed at further incentivizing investors and boosting market confidence.
- Registration Statement Filing: Can-Fite has agreed to file a registration statement with the SEC covering the ADSs issuable upon exercise of the new warrants, ensuring compliance and paving the way for future financing while enhancing company transparency.
- Clinical Trial Progress: Can-Fite's lead drug candidates, Piclidenoson and Namodenoson, are undergoing pivotal Phase III clinical trials, which, if successful, could tap into multi-billion dollar markets, further solidifying the company's position in the biopharmaceutical sector.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 100 Points
- Dow Jones Performance: The Dow Jones index gained over 100 points on Wednesday, rising 0.25% to close at 48,622.74, indicating positive market sentiment and increased investor confidence.
- NASDAQ and S&P 500 Rise: The NASDAQ climbed 0.69% to 22,672.12, while the S&P 500 rose 0.37% to 6,841.53, reflecting strong performances in the technology and consumer sectors.
- Abercrombie & Fitch Earnings: The company reported Q4 earnings of $3.68 per share, beating analyst expectations of $3.57, yet its stock fell around 5%, indicating market concerns about future performance.
- Private Sector Job Data: U.S. private businesses added 63,000 jobs in February, significantly exceeding market estimates of 50,000, suggesting a robust economic recovery that could positively impact the stock market.
See More
Can-Fite BioPharma Shares Surge 40% on Positive Trial Results
- Clinical Trial Success: Can-Fite BioPharma reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma, leading to a more than 40% surge in pre-market trading.
- Safety Endpoint Met: The trial met its primary safety endpoint, demonstrating that the drug was very well tolerated with no new safety concerns, indicating its potential for use in high-risk patients.
- Patient Recruitment: The study enrolled 20 high-risk patients who had previously received one or more therapies, highlighting the drug's prospects in treating refractory cancer cases.
- FDA Orphan Drug Designation: Namodenoson has received Orphan Drug Designation from the U.S. FDA for pancreatic cancer treatment, further enhancing its market potential and research value.
See More
UiPath to Join S&P Midcap 400 Index Effective January 2, 2026
- Market Focus: UiPath Inc. announced it will join the S&P Midcap 400 Index on January 2, 2026, replacing Synovus Financial Corp., a move expected to enhance the company's visibility and investor confidence.
- Stock Price Surge: Following this announcement, UiPath shares rose 6.8% to $17.05 in after-hours trading, reflecting market optimism regarding its future performance.
- FDA Approval: Agios Pharmaceuticals' AQVESME™ (mitapivat) received FDA approval for treating anemia in adults with alpha- or beta-thalassemia, although its stock fell 1.4%, this approval could pave the way for future sales growth.
- Stock Buyback Plan: Ramaco Resources announced a $100 million stock repurchase plan, with shares jumping 7.1% in after-hours trading, indicating the company's confidence in its value and potentially attracting more investor interest.
See More
